Millennium Retains Velcade U.S. Rights; J&J Picks Up Half Of R&D Costs
Executive Summary
Millennium's Velcade agreement with Johnson & Johnson allows the biotech company to retain rights to the oncologic in the U.S., while requiring J&J to pick up nearly half of future worldwide development costs
You may also be interested in...
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies